Assays > HLA-B1502 > Pharmacogenetics

HLA-B1502 PCR Assay

Name: HLA-B1502 PCR Assay - Goffin Molecular Technologies
Availability: InStock

Assays > HLA-B1502 > Pharmacogenetics

HLA-B1502 PCR Assay

Product highlights

Screening HLA-B*15:02 allele
Rapid results
Accurate detection

HLA-B1502 PCR Assay

Packaging

Clear

Add to quote

About HLA-B1502 PCR Assay

The Viennalab RealFast™ Assays for the HLA-B15:02 allele provide a reliable and efficient way to prevent severe hypersensitivity reactions in patients prescribed carbamazepine. Carbamazepine can cause severe hypersensitivity reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and severe drug reaction with eosinophilia and systemic symptoms (DRESS) in approximately 5% to 10% of individuals.

The prevalence of HLA-B15:02 can be as high as 25% in many Asian populations, and this allele is strongly associated with carbamazepine-induced SJS/TEN. Genotyping patients prior to starting therapy can significantly reduce the incidence of severe hypersensitivity reactions.

Specifications of the HLA-B1502 PCR Assay

HLA-B1502 RealFast™ PCR Kit for Carbamazepine Hypersensitivity Screening

Carbamazepine is a widely prescribed medication for conditions such as epilepsy, bipolar disorder, and nerve pain. However, for some patients, it can cause severe hypersensitivity reactions like Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms (DRESS). These conditions are potentially life-threatening, especially in individuals carrying certain genetic markers. The HLA-B15:02 RealFast™ PCR kits from Viennalab offer a quick and reliable way to screen for these genetic variants, helping clinicians identify patients who are at higher risk before starting carbamazepine therapy.

The HLA-B15:02 allele is strongly linked to carbamazepine-induced SJS and TEN, particularly in Asian populations where up to 25% of people may carry this gene. By using the RealFast™ assays to screen for these alleles, healthcare providers can significantly reduce the risk of severe adverse reactions, as recommended by the FDA and the Clinical Pharmacogenetic Implementation Consortium (CPIC).

These PCR kits provide fast and accurate results, making it easier to make informed decisions about whether to prescribe carbamazepine. Both assays are simple to use and highly reliable, ensuring that patients receive the safest possible treatment. With the HLA-B15:02 RealFast™ PCR kits, you can offer personalized care and minimize the risk of serious drug reactions in your patients.